ALSO READHigh expectations from Q4FY17 earnings may not materialise Multiple growth pills should keep Natco Pharma's revenue charts healthy Natco Pharma gains on USFDA nod for generic Bendamustine HCL powder Delhi HC rules in favour of Indian pharma manufacturers Natco and Alembic Natco Pharma gets environmental nod for API plant expansion in Telangana
Natco Pharma has registered a nearly threefold growth in consolidated net profit at Rs 176.4 crore in the quarter ended March, 2017 when compared to Rs 62.8 crore in the corresponding quarter previous year.
The Hyderabad-based company's consolidated revenues increased 46 per cent to Rs 577.2 crore in the fourth quarter under review as compared to Rs 394.8 crore in the year ago period.
Natco's net profit for financial year 2016-17 has grown three times at Rs 484.9 crore from Rs 155.8 crore in the previous year. Its overall revenues have doubled to Rs 2,078.9 crore.
"The revenue and profit growth for the company during the financial year was driven primarily due to the sales of the generic Oseltamivir product in the US market and continued growth of domestic formulations business," Natco said in a statement.
The company's shares ended 5.7 per cent up at Rs 939.65, on the Bombay Stock Exchange on Tuesday.